AREXVY

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Finland, France, Italy, Lithuania, UK.

Active ingredients

The drug AREXVY contains one active pharmaceutical ingredient (API):

1	RSVPreF3 antigen
	RSV glycoprotein F antigen is designed to enhance antigen-specific cellular immune response and neutralizing antibodies response in individuals with pre-existing immunity against RSV. The adjuvant AS01E facilitates the recruitment and activation of antigen presenting cells carrying vaccine-derived antigens in the draining lymph node, which in turn leads to the generation of RSVPreF3-specific CD4+ T cells.
	Read more about RSV glycoprotein F antigen

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
AREXVY Powder for suspension for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J07BX05		J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BX Other viral vaccines
Discover more medicines within J07BX05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3040399, 3040401
FI	Lääkealan turvallisuus- ja kehittämiskeskus	041312
FR	Base de données publique des médicaments	64431629
IT	Agenzia del Farmaco	050751015, 050751027
LT	Valstybinė vaistų kontrolės tarnyba	1097246, 1097247
US	FDA, National Drug Code	58160-723, 58160-744, 58160-848